Effect of ezetimibe on low- and high-density lipoprotein subclasses in sitosterolemia

EZE improves VLDL and HDL subfraction distribution, thereby reducing the atherogenic lipid profile, thus providing potential clinical benefit in sitosterolemia beyond TC and PS reduction.